Avid Bioservices

Avid Bioservices, Inc. engages in the commercial manufacturing. The firm focuses on the biopharmaceutical products derived from mammalian cell culture for culture for biotechnology and pharmaceutical companies. It specializes in clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory submissions and support. The company was founded on June 3, 1981 and is headquartered in Tustin, CA.

Avid Bioservices, Inc. engages in clinical and commercial manufacturing of biologics. It focuses on the biopharmaceutical products derived from mammalian cell culture for culture for biotechnology and pharmaceutical companies. It specializes in clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory submissions and support. The company was founded on June 3, 1981 and is headquartered in Tustin, CA.

-- Recorded First Quarter Revenue of $25.4 Million --   -- S igned Three New Customers and Project Expansion Orders with Current Customers for $20 Million  --

Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2020 and Recent Developments

TUSTIN, Calif., Aug.  26, 2020  (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that Mapp Biopharmaceutical, Inc., has contracted Avid to provide process transfer, scale-up and clinical manufacturing services to support one of its development programs for a novel antiviral drug candidate. Avid and Mapp will immediately commence the initial phase of the project.

Avid Bioservices Selected by Mapp Biopharmaceutical, Inc. for Clinical Development of Novel Human Monoclonal Antiviral Antibody

TUSTIN, Calif., Aug.  25, 2020  (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the first quarter of fiscal year 2021 on September 1, 2020 after market close and will host a conference call and webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time).  Members of Avid's senior management will discuss financial results for the first quarter and review recent corporate developments.

Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2021 After Market Close on September 1, 2020

TUSTIN, Calif., Aug.  06, 2020  (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that Iovance Biotherapeutics (NASDAQ: IOVA) has selected Avid to provide process development, pilot-batch manufacturing and CGMP manufacturing services to support development of IOV-3001, a novel antibody cytokine engrafted protein.

Avid Bioservices Selected By Iovance Biotherapeutics to Lead Process Development Through CGMP Manufacturing of Novel IL-2 Analog, IOV-3001

Argonaut’s Clinical Fill-Finish Capabilities to Complement Avid’s Upstream and Downstream Process Development and Biologics Manufacturing Services in Supporting Developers of Biologic Therapeutics Argonaut’s Clinical Fill-Finish Capabilities to Complement Avid’s Upstream and Downstream Process Development and Biologics Manufacturing Services in Supporting Developers of Biologic Therapeutics

Avid Bioservices and Argonaut Manufacturing Services Enter Agreement to Offer Biotechnology and Pharmaceutical Clients Integrated Process Development, Drug Substance Manufacturing and Drug Product Parenteral Manufacturing

Avid Bioservices (CDMO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Avid Bioservices (CDMO) Catches Eye: Stock Jumps 5.4%

The company still had significant production problems. But it also picked up a lot of new business in Q4.

How Avid Bioservices Beat Wall Street Estimates in Q4

Investors need to pay close attention to Avid Bioservices (CDMO) stock based on the movements in the options market lately.

Implied Volatility Surging for Avid Bioservices (CDMO) Stock Options

Avid Bioservices, Inc. (CDMO) CEO Richard Hancock on Q4 2020 Results - Earnings Call Transcript

-- Appointed Nicholas Green as President and Chief Executive Officer --   -- Recorded Fourth Quarter Revenue of $12.6 Million and Annual Revenue of $59.7 Million --

Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2020 and Recent Developments

Seasoned Executive Brings More than 30 Years of Pharmaceutical and Healthcare Services Industry Experience to Lead Avid Through Next Phase of Growth and Expansion Seasoned Executive Brings More than 30 Years of Pharmaceutical and Healthcare Services Industry Experience to Lead Avid Through Next Phase of Growth and Expansion

Avid Bioservices Names Nicholas Green as President and Chief Executive Officer

Avid Bioservices (CDMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Avid Bioservices (CDMO) to Report a Decline in Earnings: What to Look Out for

Full Service “Sequence-to-Manufacturing” Offering Designed to Drive Efficiencies and Reduce Overall Timelines for Delivering Early-Stage CGMP Bulk Drug Substances Full Service “Sequence-to-Manufacturing” Offering Designed to Drive Efficiencies and Reduce Overall Timelines for Delivering Early-Stage CGMP Bulk Drug Substances

Avid Bioservices and Aragen Bioscience Enter Agreement to Offer Biotechnology and Pharmaceutical Clients Integrated Solution for Cell Line and Process Development through Commercial Manufacturing

TUSTIN, Calif., April  13, 2020  (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced the appointment of two senior directors of business development with responsibility for driving CDMO business growth within North America, Europe and Asia.  Jason C. Brady, Ph.D. will serve as senior director of business development for the eastern region of North America, as well as Europe.  Sylvia Hinds has been named senior director of business development for the western region of North America in addition to the Asia Pacific region.

Avid Bioservices Announces Appointment of Two Senior Directors of Business Development with Responsibility for North America, Europe and Asia

Company Honored for Capabilities, Expertise, Reliability, Compatibility, and Service in the Contract Development and Manufacturing Industry

Avid Bioservices Receives Five 2020 CMO Leadership Awards

The drug manufacturer encountered an operational setback, which forced it to slash revenue guidance.

Here's Why Avid Bioservices Tumbled Today

Avid Bioservices, Inc. (CDMO) CEO Richard Hancock on Q3 2020 Results - Earnings Call Transcript

Avid Bioservices (NASDAQ:CDMO) reported Q3 results. Quarterly Results • Earnings per share decreased 20% year over year to a loss of $0.06, which missed the estimate by $0.02.

Recap: Avid Bioservices Q3 Earnings

TUSTIN, Calif., March  04, 2020  (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock").

Avid Bioservices  Declares Quarterly Dividend on Its Series E Convertible Preferred Stock

Will Avid Bioservices (CDMO) Report Negative Q3 Earnings? What You Should Know

Company Adds Seasoned Professional with Over 20 Years of Commercial Operations and Sales Team Management Experience Company Adds Seasoned Professional with Over 20 Years of Commercial Operations and Sales Team Management Experience

Avid Bioservices Appoints Timothy Compton as Chief Commercial Officer

The drug manufacturing company reported operating results for its fiscal second quarter.

Here's Why Avid Bioservices Jumped as Much as 22.2% Today

Avid Bioservices, Inc. (CDMO) CEO Rick Hancock on Q2 2020 Results - Earnings Call Transcript

-- Achieved Strong Second Quarter Revenue of $18.3 Million and Gross Margin of 18% --    -- Fiscal 2020 Projected Revenue of $64 to $67 Million Reaffirmed --

Avid Bioservices Reports Financial Results for Second Quarter Fiscal 2020 and Recent Developments

TUSTIN, Calif., Dec.  04, 2019  (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock").

News for Avid Bioservices Stock (CDMOP)